Menu

Epilepsy

Heart Structure and Function in Temporal Lobe Epilepsy (TLE)

Summary:  Evaluate whether people with TLE have systematic differences in heart structure or function compared to people without epilepsy.

Funding Source:  Internal

Principal Investigator:  Arthur C. Grant, MD, PhD

Co-Investigators:  Mark Stewart, MD, PhD and Jason Lazar, MD

Contact: Nadege Gilles (718) 270-7786

Psychological Aspects of Treatment Adherence and Quality of Life Epilepsy 

Summary: To recruit predominantly ethnic minority PWE from SUNY DMC and University Hospital of Brooklyn at long Island college Hospital for cross-sectional study of psychosocial and factors and their association with treatment adherence an quality of life. 2 visits ( about 4hrs each a month apart).  Interviews and surveys during the visits.

Funding Source:  Internal

Principal Investigators:  Arthur C. Grant, MD, PhD and Luba Nakhutina, PhD

Contact: Nadege Gilles (718) 270-7786

Regulatory RNA in Epilepsy

Summary:  There are several types of RNA in cells. Regulatory RNA can affect how nerve cells in the brain communicate with each other. We are studying whether mutations in regulatory RNA are associated with epilepsy.

Funding Source:  Internal

Principal Investigators:  Henri Tiedge, PhD, Arthur C. Grant, MD, PhD, and Arthur Rose, MD

Contact: Nadege Gilles (718) 270-7786

A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Pregabalin as Adjunctive Therapy in Children 1 Month Through <4 Years of Age with Partial Onset Seizures

Funding Source: Pfizer, Inc.

Principal Investigator:  Arthur C. Grant, MD

Co-Investigators: Geetha Chari, MD

Contact: Nadege Gilles (718) 270-7786

A 12-Month Open-Label Study To Evaluate The Safety And Tolerability Of Pregabalin As Adjunctive Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures

 Funding Source: Pfizer, Inc.

Principal Investigator:  Arthur C. Grant, MD

Co-Investigators: Katherine Mortati, MD, and Ewa Koziorynska, MD

Contact: Nadege Gilles (718) 270-7786

An Open-Label,  Randomized, Crossover Pharmacokinetic Study to Determine Relative Bioavailability, Safety and Tolerability of Single Doses of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®) in Patients with Refractory Epilepsy

Summary:  The main purpose of this study is to compare absorption into the body of an investigational formulation of diazepam given as a nasal spray compared to an equal dose of Diastat® given as a rectal gel.

Funding Source: Acorda Therapeutics, Inc   

Principal Site Investigator:  Arthur C. Grant, MD, PhD

Co-Investigators: Katherine Mortati, MD, Ewa Koziorynska, MD, Belinda Oyinkan Marquis, MD

Contact: Nadege Gilles (718) 270-7786

Putting EEG in the Emergency Department (ED)

Summary:  This study involved the evaluation of a new device - microEEG ® - to record EEGs in patients with altered mental status in the adult ER. Dr. Chari was the primary EEGer in the pilot phase of the study, and later actively participated by being on call and reviewing the EEGs done emergently in the ER. The device was found to be non-inferior to the standard EEG recording machines. The second phase of the study involved evaluation of the management of patients with altered mental status in the adult ED, with (and without) recording EEGs, and determining results.

Start Date: 2010

End Date: 2013

Funding Source: NIH

Principal Site Investigators: Andre Fenton, PhD and Shahriar Zehtabchi, MD

Contact: Study completed, no longer enrolling

Wireless Novel microEEG for Neonatal Apnea and Community Neurological Network

Summary: 

Start Date: 2012

End Date: 2016

Funding Source: NIH

Principal Site Investigator: Geetha Chari, MD, Dr. Z. Ibrahim, and Dr. S. Baki

Contact: Dr. Z. Ibrahim and Dr. S. Baki

ESETT

Established status epilepticus treatment trial

Summary:  The primary objective is to determine the most effective and/or the least effective treatment of benzodiazepine-refractory status epilepticus (SE) among patients older than 2 years. There are three active treatment arms being compared: fosphenytoin (FOS), levetiracetam (LEV), and valproic acid (VPA).

Start Date: October 2015

End Date: 2019

Funding Source: NIH

Principal Site Investigators: Shahriar Zehtabchi, MD (UHB/KCH) and Geetha Chari, MD

Co-Investigators: Katherine Mortati, MD and Helen Valsamis, MD

Contacts: Sarah Weingast (UHB) and Bryce Petty (KCH)